Target intelligence / Profile preview

Ovomucoid (Gal d 1)

Target
Gal d 1
Molecular classification
Serine protease inhibitor, Kazal-type inhibitor, Glycoprotein, Allergen
01

Overview

Ovomucoid, also known as Gal d 1, is the primary allergenic protein found in hen's egg white, accounting for approximately 11% of its total protein content [1, 4]. It is a highly glycosylated, heat-stable protein belonging to the Kazal-type serine protease inhibitor family, characterized by three tandem domains that exhibit potent trypsin inhibitory activity [1, 6]. Biologically, it serves to protect the developing avian embryo by inhibiting bacterial and endogenous proteases [6, 13]. In clinical medicine, ovomucoid is a critical target for the diagnosis and management of egg allergy, as its resistance to heat and digestive enzymes makes it a major cause of persistent allergic reactions even to cooked eggs [4, 8]. Therapeutic strategies involving ovomucoid focus on oral immunotherapy (OIT) to induce desensitization and the development of hypoallergenic recombinant variants for safer treatment [14, 15]. Additionally, its role as a biomarker (specific IgE to Gal d 1) is essential for predicting whether a patient will react to baked or raw egg products [4, 5].

Other names
Gal d 1Gal d IChicken ovomucoidEgg white trypsin inhibitorOVM
02

Mechanism of action

Induction of immune tolerance through oral immunotherapy and competitive inhibition of trypsin

03

Biological functions

Protease inhibitionTrypsin inhibitionEmbryo protectionAntibacterial activityImmune response induction
04

Disease associations

Egg allergyAnaphylaxisAtopic dermatitisEosinophilic esophagitisAsthma
05

Safety considerations

Risk of systemic anaphylaxisHeat and acid stabilityCross-reactivity with other avian speciesPersistent allergenicity after cooking
06

Interacting drugs

Epinephrine

3 more in the full profile.

07

Biomarkers

Specific IgE to Gal d 1Skin prick test reactivityBasophil activationTh1/Th2 cytokine ratioSerum tryptase

Beyond the preview

Go deeper on Ovomucoid (Gal d 1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovomucoid (Gal d 1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call